Liu Ning, Shimizu Shinya, Ito-Ihara Toshiko, Takagi Kuniaki, Kita Toru, Ono Takahiko
Clinical Pharmacology & Therapeutics, University of Shizuoka School of Pharmaceutical Sciences, Shizuoka, Japan.
Nephron Exp Nephrol. 2007;105(3):e65-74. doi: 10.1159/000098321. Epub 2006 Dec 29.
Previously we observed that the coagulation system promotes matrix protein accumulation through transforming growth factor (TGF)-beta and connective tissue growth factor (CTGF) expression in rat mesangioproliferative glomerulonephritis (MsPGN). Angiotensin II receptor blockers (ARBs) are known to suppress matrix accumulation in experimental MsPGN. In the present study, we investigated whether ARB suppresses MsPGN through inhibition of these profibrotic cytokines, and in relation to coagulation and fibrinolytic systems.
MsPGN was induced in Wistar rats by intravenous injection of anti-Thy-1.1 monoclonal antibody, OX-7. As an ARB, olmesartan was orally administered in rat feed from the day of OX-7 injection (day 0) to day 8, when rats were sacrificed and kidney specimens were collected. The degrees of cellular proliferation, matrix production, coagulation factors, and inhibitory factor of fibrinolysis were evaluated.
Although blood pressure did not change in the normal, disease control, or treatment groups, the amount of urinary protein was significantly decreased in the ARB-treated groups, compared with the disease control group (p < 0.05). alpha-Smooth muscle actin expression was suppressed significantly in the treatment groups (p < 0.001). Blue-staining areas of trichrome, the number of proliferating cell nuclear antigen (PCNA)- or ED-1-positive cells, fibronectin and plasminogen activator inhibitor type 1 in glomeruli significantly decreased in the treatment groups (p < 0.05, respectively); however, fibrin-related antigen and factor V depositions were not suppressed in the treatment groups.
These results suggest that the ARB drug would ameliorate MsPGN in vivo, at least partly through CTGF and plasminogen activator inhibitor type 1 suppression, and independently of the local coagulation system in glomeruli.
此前我们观察到,在大鼠系膜增生性肾小球肾炎(MsPGN)中,凝血系统通过转化生长因子(TGF)-β和结缔组织生长因子(CTGF)的表达促进基质蛋白积累。已知血管紧张素II受体阻滞剂(ARB)可抑制实验性MsPGN中的基质积累。在本研究中,我们调查了ARB是否通过抑制这些促纤维化细胞因子来抑制MsPGN,以及与凝血和纤溶系统的关系。
通过静脉注射抗Thy-1.1单克隆抗体OX-7在Wistar大鼠中诱导MsPGN。作为ARB药物,从注射OX-7当天(第0天)至第8天,将奥美沙坦加入大鼠饲料中口服给药,之后处死大鼠并收集肾脏标本。评估细胞增殖、基质产生、凝血因子和纤溶抑制因子的程度。
虽然正常组、疾病对照组或治疗组的血压没有变化,但与疾病对照组相比,ARB治疗组的尿蛋白量显著降低(p<0.05)。治疗组中α-平滑肌肌动蛋白的表达明显受到抑制(p<0.001)。治疗组中肾小球三色染色的蓝色区域、增殖细胞核抗原(PCNA)或ED-1阳性细胞的数量、纤连蛋白和纤溶酶原激活物抑制剂1型显著减少(分别为p<0.05);然而,治疗组中纤维蛋白相关抗原和因子V的沉积并未受到抑制。
这些结果表明,ARB药物可在体内改善MsPGN,至少部分是通过抑制CTGF和纤溶酶原激活物抑制剂1型,且独立于肾小球局部凝血系统。